- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
IGBA Launches Panel of 13 CEO-Level Advisers
The IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high-quality, safe, and effective medicines while reducing costs in pharmaceutical care.
The International Generic and Biosimilar Medicines Association (IGBA) has formed a CEO Advisory Committee with 13 leaders from companies based in Europe, the United States, Canada, India, Israel, and Japan.
The IGBA, which dates to 1997 when it was founded as the International Generic Pharmaceutical Alliance, is incorporated in Geneva, Switzerland, and is an accredited member of the World Health Organization. According to the group’s website, the IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high quality, safe, and effective medicines while reducing costs in pharmaceutical care.
Vivian Frittelli, IGBA chair, said forming the CEO Advisory Committee will be a “transformative” step for the group. “This is the first time that the generic and biosimilar medicines industry’s company leadership has united in a structured framework, enabling a collective voice in the global pharmaceutical space,” he added.
Members of the CEO Advisory Committee include:
- Chirag Patel, president and Co-CEO of Amneal Pharmaceuticals Inc.
- Jeff Watson, president and CEO of Apotex Inc.
- Pankaj Patel, chairman of Cadila Healthcare Ltd.
- Samina Hamied, executive vice chair of Cipla Ltd.
- Satish Reddy, chair of Dr. Reddy’s Laboratories Ltd.
- Lucas Sigman, CEO of Insud Pharma S.L.
- Vinita Gupta, CEO of Lupin Ltd.
- Richard Saynor, CEO of Sandoz AG.
- Peter Goldschmidt, CEO and chairman, Executive Board, STADA Arzneimittel AG
- Dilip Shanghvi, managing director, Sun Pharmaceutical Industries Ltd.
- Kåre Schultz, president and CEO, Teva Pharmaceuticals Industries Ltd.
- David Peix, CEO, Towa Pharma International Holdings S.L.
- Michael Goettler, CEO of Viatris Inc.
"I am happy to join the CEO Advisory Committee set up by the IGBA,” said Shanghvi, of Sun Pharmaceuticals. “The generic and biosimilar industry leaders of 13 leading multinational companies coming together for the first time to discuss critical global healthcare policy issues is a great step."
Added Peix, of Towa Pharma, "This advisory committee represents a milestone for the 13 worldwide leading companies of generic, value added and biosimilar medicines. For the first time, we are officially together on facing the main actual challenges and we are all working by our common purpose: the patients."
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
